Nektar Therapeutics Raises $250 Million After Alopecia Drug Sends Stock Up 18%

NEW YORK, April 21 —

Nektar Therapeutics launched a $250 million common stock offering the same week its alopecia drug data sent shares up 18.3%.

What Actually Happened

Nektar got good drug data and immediately monetized the enthusiasm. That's not a criticism. It's the biotech playbook, and Nektar ran it cleanly. Positive alopecia trial results drove the stock up 18.3%, and within the same stretch the company filed a $250mn common stock offering to raise cash while the price was elevated.

The raise is significant relative to the company's size. Nektar generates $55mn in trailing twelve-month revenue and trades at a negative 8.8x forward P/E, meaning Wall Street still expects losses ahead. That $250mn buys runway. Alopecia is a large addressable market with limited competition in certain segments, and Nektar clearly wants enough cash to push through later-stage trials without coming back to the capital markets at a worse price.

The Catch

Two problems. First, the offering itself. Raising $250mn in common stock against $55mn in revenue means real dilution for anyone who bought the pop. The 18.3% gain starts looking thinner once new shares hit the float. Biotech investors know this dynamic: the rally that funds the raise is often the rally you should have sold into.

Second, there's a securities class action lawsuit with a May 5 deadline hanging over the stock. Lawsuits in biotech are common and often go nowhere, but the timing creates noise right when the company needs clean momentum for Citi's 30-day catalyst window. If detailed trial data lands during that window and impresses, none of this matters. If the data underwhelms, the combination of dilution, litigation, and fading hype could compress the stock fast.

Bottom Line

This is a bet on pipeline, not fundamentals. At negative forward earnings and $55mn in revenue, Nektar is priced entirely on what its alopecia program could become. The $250mn raise is smart treasury management. You raise when you can, not when you need to. But for anyone buying today, the entry price already reflects the good news, and the share count is about to go up.

Watch the offering's final pricing and the Phase trial data readout within Citi's catalyst window. Those two events will determine whether the 18% move was the beginning or the top.

Want to see Nektar's full financial breakdown, valuation, and risk profile? Generate a free NKTR report on Basis Report.

Basis Report does not hold positions in securities discussed. This is not investment advice.